Record High Sales Based on Strong Performance in Out-of-Hospital Prescriptions
Surpassing 2015 Results
Beijing Hanmi Sales Exceed 300 Billion KRW
[Asia Economy Reporter Myunghwan Lee] Hanmi Pharm recorded sales exceeding 1.3 trillion KRW last year, achieving the highest sales in its history since its founding.
Hanmi Pharm announced on the 8th that its consolidated sales and operating profit for 2022 were tentatively estimated at 1.3317 trillion KRW and 157 billion KRW, respectively. This represents a 10.7% increase in sales and a 25.2% increase in operating profit compared to the previous year. During the same period, net profit reached 95.7 billion KRW, growing by 17.4%. Last year, Hanmi Pharm invested 177.9 billion KRW, equivalent to 13.4% of sales, in research and development (R&D).
Hanmi Pharm explained that last year's sales surpassed the 1.3175 trillion KRW sales recorded in 2015, when it achieved the largest domestic new drug license contract. Furthermore, it emphasized that it recorded the highest sales despite no major new drug achievements this year.
Hanmi Pharm stated, "We achieved the highest performance since our founding through growth based on self-developed products." Hanmi Pharm achieved 789.1 billion KRW in out-of-hospital prescription sales last year, marking the fifth consecutive year as the number one in domestic out-of-hospital prescription sales.
The strong sales of flagship products led to the excellent performance. The dyslipidemia combination drug 'Rosuzet' alone achieved prescription sales of 140.3 billion KRW, and Hanmi launched 18 blockbuster products with sales exceeding 10 billion KRW each. Hanmi's representative combination drug family, the 'Amozalatan Family,' recorded combined prescription sales of 130.5 billion KRW.
Hanmi Pharm's local Chinese subsidiary, Beijing Hanmi Pharm, also surpassed 300 billion KRW in annual sales for the first time since its founding. Beijing Hanmi Pharm experienced somewhat sluggish sales at the end of the year due to the large-scale COVID-19 outbreak in China during the fourth quarter. Looking at the entire year, it achieved cumulative sales of 350.6 billion KRW, operating profit of 78 billion KRW, and net profit of 71.5 billion KRW.
A Hanmi Pharm official said, "Last year, under the banner of 'sustainable innovation management,' we achieved sustainable growth through self-developed products and made intensive investments in R&D for the future. In this year, marking the 50th anniversary of our founding, we will do our best to produce more substantial and solid results than in previous years."
Hanmi Science, the holding company of Hanmi Pharm Group, recorded consolidated sales of 1.046 trillion KRW, operating profit of 65.9 billion KRW, and net profit of 55.5 billion KRW in 2022. Hanmi Science is expanding its business through synergies with affiliates such as Hanmi Pharm, JVM, and Online Pharm.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
